NanoCarrier Co., Ltd. (4571.T)
JPY 150.0
(-1.96%)
JPY 150.0
(-1.96%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.1 Billion JPY | 0.0% |
| 2022 | 1.1 Billion JPY | -3.57% |
| 2021 | 1.15 Billion JPY | 0.0% |
| 2020 | - JPY | 0.0% |
| 2019 | - JPY | -100.0% |
| 2018 | 2.47 Billion JPY | 0.0% |
| 2017 | 2.47 Billion JPY | 0.0% |
| 2016 | 2.47 Billion JPY | -17.5% |
| 2015 | 3 Billion JPY | 0.0% |
| 2014 | - JPY | -100.0% |
| 2013 | 540 Million JPY | -48.08% |
| 2012 | 1.04 Billion JPY | -38.82% |
| 2011 | 1.7 Billion JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| 2007 | - JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.1 Billion JPY | -0.08% |
| 2023 Q3 | 1.1 Billion JPY | 0.0% |
| 2023 FY | 1.1 Billion JPY | 0.0% |
| 2023 Q4 | 1.1 Billion JPY | 0.0% |
| 2023 Q1 | 1.1 Billion JPY | 0.0% |
| 2023 Q2 | 1.1 Billion JPY | 0.0% |
| 2022 Q4 | 1.1 Billion JPY | 3253.04% |
| 2022 Q3 | 33.07 Million JPY | -97.12% |
| 2022 FY | 1.1 Billion JPY | -3.57% |
| 2022 Q1 | 1.15 Billion JPY | 0.0% |
| 2022 Q2 | 1.15 Billion JPY | 0.0% |
| 2021 Q2 | 1.15 Billion JPY | 0.0% |
| 2021 Q4 | 1.15 Billion JPY | 0.0% |
| 2021 FY | 1.15 Billion JPY | 0.0% |
| 2021 Q1 | 1.15 Billion JPY | 0.0% |
| 2021 Q3 | 1.15 Billion JPY | 0.0% |
| 2020 FY | - JPY | 0.0% |
| 2020 Q1 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q4 | - JPY | 0.0% |
| 2019 Q1 | 527.62 Million JPY | -78.68% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 Q4 | - JPY | 0.0% |
| 2019 FY | - JPY | -100.0% |
| 2019 Q2 | - JPY | -100.0% |
| 2018 Q1 | 2.47 Billion JPY | 0.0% |
| 2018 Q3 | 2.47 Billion JPY | 0.0% |
| 2018 Q4 | 2.47 Billion JPY | 0.0% |
| 2018 FY | 2.47 Billion JPY | 0.0% |
| 2018 Q2 | 2.47 Billion JPY | 0.0% |
| 2017 Q2 | 2.47 Billion JPY | 0.0% |
| 2017 Q4 | 2.47 Billion JPY | 0.0% |
| 2017 FY | 2.47 Billion JPY | 0.0% |
| 2017 Q1 | 2.47 Billion JPY | 0.0% |
| 2017 Q3 | 2.47 Billion JPY | 0.0% |
| 2016 Q3 | 2.47 Billion JPY | 0.0% |
| 2016 FY | 2.47 Billion JPY | -17.5% |
| 2016 Q1 | 2.47 Billion JPY | -17.5% |
| 2016 Q4 | 2.47 Billion JPY | 0.0% |
| 2016 Q2 | 2.47 Billion JPY | 0.0% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 Q1 | - JPY | 0.0% |
| 2015 FY | 3 Billion JPY | 0.0% |
| 2015 Q3 | 3 Billion JPY | 0.0% |
| 2015 Q4 | 3 Billion JPY | 0.0% |
| 2014 Q4 | - JPY | -100.0% |
| 2014 Q3 | 540 Million JPY | 0.0% |
| 2014 FY | - JPY | -100.0% |
| 2014 Q1 | 540 Million JPY | 0.0% |
| 2014 Q2 | 540 Million JPY | 0.0% |
| 2013 Q1 | 860 Million JPY | -17.31% |
| 2013 FY | 540 Million JPY | -48.08% |
| 2013 Q2 | 540 Million JPY | -37.21% |
| 2013 Q3 | 540 Million JPY | 0.0% |
| 2013 Q4 | 540 Million JPY | 0.0% |
| 2012 FY | 1.04 Billion JPY | -38.82% |
| 2012 Q1 | 1.7 Billion JPY | 0.0% |
| 2012 Q2 | 1.7 Billion JPY | 0.0% |
| 2012 Q3 | 1.7 Billion JPY | 0.0% |
| 2012 Q4 | 1.04 Billion JPY | -38.82% |
| 2011 Q4 | 1.7 Billion JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 FY | 1.7 Billion JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2008 Q3 | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | -44.572% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 44.554% |
| Linical Co., Ltd. | 1.49 Billion JPY | 26.07% |
| Trans Genic Inc. | 1.32 Billion JPY | 16.439% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -141886.684% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 52.753% |
| AnGes, Inc. | 214.94 Million JPY | -415.897% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -937.835% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 98.246% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | -1211.38% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -3804.359% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | -26.647% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -2739.734% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 39.666% |
| PeptiDream Inc. | 19.63 Billion JPY | 94.352% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | -588.34% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | -179.324% |
| Healios K.K. | 450 Million JPY | -146.426% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | -1334.728% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | -43.402% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | -40.725% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | -125.687% |
| StemCell Institute Inc. | 6.67 Million JPY | -16510.485% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | -671.42% |